Effects of delisting nonprescription combination drugs on health insurance expenditures for pharmaceuticals in Korea

Chan Mi Park, Kun Sei Lee, Euna Han, Dong Sook Kim

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In November 2006, 727 combination drugs in 24 therapeutic classes were delisted in the national formulary in Korea to reduce the country's pharmaceutical expenditure, making these 727 drugs non-reimbursable. This study examines the effects of this delisting on national health insurance expenditures for pharmaceuticals. An interrupted time series analysis was conducted for the period from January 2005 to August 2007 by using administrative claims from Korea's National Health Insurance. The main outcome variable was the total pharmaceutical expenditure measured as a whole and based on the level of health care institutions and therapeutic classes. Comparison between exposure group (delisted drugs) and non-exposure group (listed drugs) were done. No changes in the level of or trend in the total pharmaceutical expenditure were detected. However, the delisting reduced pharmaceutical expenditures in clinics. Delisting effects were also observed according to therapeutic classes of drugs. The results indicate that any delisting should take into account the type of drug.

Original languageEnglish
Pages (from-to)590-595
Number of pages6
JournalHealth Policy
Volume120
Issue number6
DOIs
Publication statusPublished - 2016 Jun 1

Fingerprint

Nonprescription Drugs
Health Insurance
Korea
Health Expenditures
Pharmaceutical Preparations
National Health Programs
Pharmacopoeias
Drug Combinations
Health Status
Therapeutics

All Science Journal Classification (ASJC) codes

  • Health Policy

Cite this

@article{c87b43e2797f4338a052f427d3f966f1,
title = "Effects of delisting nonprescription combination drugs on health insurance expenditures for pharmaceuticals in Korea",
abstract = "In November 2006, 727 combination drugs in 24 therapeutic classes were delisted in the national formulary in Korea to reduce the country's pharmaceutical expenditure, making these 727 drugs non-reimbursable. This study examines the effects of this delisting on national health insurance expenditures for pharmaceuticals. An interrupted time series analysis was conducted for the period from January 2005 to August 2007 by using administrative claims from Korea's National Health Insurance. The main outcome variable was the total pharmaceutical expenditure measured as a whole and based on the level of health care institutions and therapeutic classes. Comparison between exposure group (delisted drugs) and non-exposure group (listed drugs) were done. No changes in the level of or trend in the total pharmaceutical expenditure were detected. However, the delisting reduced pharmaceutical expenditures in clinics. Delisting effects were also observed according to therapeutic classes of drugs. The results indicate that any delisting should take into account the type of drug.",
author = "Park, {Chan Mi} and Lee, {Kun Sei} and Euna Han and Kim, {Dong Sook}",
year = "2016",
month = "6",
day = "1",
doi = "10.1016/j.healthpol.2016.05.003",
language = "English",
volume = "120",
pages = "590--595",
journal = "Health Policy",
issn = "0168-8510",
publisher = "Elsevier Ireland Ltd",
number = "6",

}

Effects of delisting nonprescription combination drugs on health insurance expenditures for pharmaceuticals in Korea. / Park, Chan Mi; Lee, Kun Sei; Han, Euna; Kim, Dong Sook.

In: Health Policy, Vol. 120, No. 6, 01.06.2016, p. 590-595.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of delisting nonprescription combination drugs on health insurance expenditures for pharmaceuticals in Korea

AU - Park, Chan Mi

AU - Lee, Kun Sei

AU - Han, Euna

AU - Kim, Dong Sook

PY - 2016/6/1

Y1 - 2016/6/1

N2 - In November 2006, 727 combination drugs in 24 therapeutic classes were delisted in the national formulary in Korea to reduce the country's pharmaceutical expenditure, making these 727 drugs non-reimbursable. This study examines the effects of this delisting on national health insurance expenditures for pharmaceuticals. An interrupted time series analysis was conducted for the period from January 2005 to August 2007 by using administrative claims from Korea's National Health Insurance. The main outcome variable was the total pharmaceutical expenditure measured as a whole and based on the level of health care institutions and therapeutic classes. Comparison between exposure group (delisted drugs) and non-exposure group (listed drugs) were done. No changes in the level of or trend in the total pharmaceutical expenditure were detected. However, the delisting reduced pharmaceutical expenditures in clinics. Delisting effects were also observed according to therapeutic classes of drugs. The results indicate that any delisting should take into account the type of drug.

AB - In November 2006, 727 combination drugs in 24 therapeutic classes were delisted in the national formulary in Korea to reduce the country's pharmaceutical expenditure, making these 727 drugs non-reimbursable. This study examines the effects of this delisting on national health insurance expenditures for pharmaceuticals. An interrupted time series analysis was conducted for the period from January 2005 to August 2007 by using administrative claims from Korea's National Health Insurance. The main outcome variable was the total pharmaceutical expenditure measured as a whole and based on the level of health care institutions and therapeutic classes. Comparison between exposure group (delisted drugs) and non-exposure group (listed drugs) were done. No changes in the level of or trend in the total pharmaceutical expenditure were detected. However, the delisting reduced pharmaceutical expenditures in clinics. Delisting effects were also observed according to therapeutic classes of drugs. The results indicate that any delisting should take into account the type of drug.

UR - http://www.scopus.com/inward/record.url?scp=84969983718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969983718&partnerID=8YFLogxK

U2 - 10.1016/j.healthpol.2016.05.003

DO - 10.1016/j.healthpol.2016.05.003

M3 - Article

C2 - 27241339

AN - SCOPUS:84969983718

VL - 120

SP - 590

EP - 595

JO - Health Policy

JF - Health Policy

SN - 0168-8510

IS - 6

ER -